Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.15 USD | -2.48% | +14.13% | +262.07% |
May. 10 | Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 01 | Kiromic BioPharma, Inc. announced that it has received $2 million in funding | CI |
Financials (USD)
Sales 2022 | - | Sales 2023 | - | Capitalization | 1.09M |
---|---|---|---|---|---|
Net income 2022 | -34M | Net income 2023 | -20M | EV / Sales 2022 | - |
Net Debt 2022 | 8.77M | Net Debt 2023 | 12.34M | EV / Sales 2023 | - |
P/E ratio 2022 |
-0.08
x | P/E ratio 2023 |
-0.04
x | Employees | 35 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 81.1% |
1 day | -2.48% | ||
1 week | +14.13% | ||
Current month | +19.54% | ||
1 month | +21.15% | ||
3 months | -5.97% | ||
6 months | +950.00% | ||
Current year | +262.07% |
Managers | Title | Age | Since |
---|---|---|---|
Scott Dahlbeck
FOU | Founder | 62 | 06-08-05 |
Pietro Bersani
CEO | Chief Executive Officer | 56 | 20-05-31 |
Brian Hungerford
DFI | Director of Finance/CFO | 49 | 23-06-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Nagel
CHM | Chairman | 62 | 20-05-31 |
Pamela Misajon
BRD | Director/Board Member | 65 | 23-07-19 |
Pietro Bersani
CEO | Chief Executive Officer | 56 | 20-05-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-22 | 3.15 | -2.48% | 445 |
24-05-21 | 3.23 | +4.19% | 4,548 |
24-05-20 | 3.1 | -0.32% | 3,073 |
24-05-17 | 3.11 | +0.97% | 11,719 |
24-05-16 | 3.08 | +11.59% | 2,722 |
Delayed Quote OTC Markets, May 22, 2024 at 11:20 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+262.07% | 4.86M | |
+9.99% | 115B | |
+12.01% | 106B | |
-3.07% | 24.69B | |
-0.64% | 21.97B | |
-4.64% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+33.05% | 12.13B |
- Stock Market
- Equities
- KRBP Stock